Quantcast

Latest Panitumumab Stories

2006-06-12 15:51:28

LOS ANGELES (Reuters) - Biotechnology company Amgen Inc. said on Monday that the U.S. Food and Drug Administration has agreed to a "priority review" of the company's application for experimental drug panitumumab as a treatment for colon cancer. With priority review status, the FDA will make its decision on whether to approve the drug within six months, rather than the usual 10- to 12-month review period. The agency grants priority review to products that are considered to be...

2006-06-05 07:40:00

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose Baselga,...

2006-06-04 13:45:17

LOS ANGELES (Reuters) - Amgen Inc. said on Saturday that testing tumors for the protein that its experimental colon cancer drug panitumumab is designed to target is not an accurate measure of whether a patient will respond to the treatment. Two clinical trials funded by Amgen show that some patients who tested negative for epidermal growth factor receptor, the protein on the surface of cancer cells that the drug is designed to block, responded to the treatment, while others who...

2006-06-03 15:11:46

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose...

2006-04-03 13:25:12

By Megan Rauscher WASHINGTON (Reuters Health) - Among patients with colorectal cancer that has spread to other areas of the body and who have not been helped by standard chemotherapy, a new drug called panitumumab produces a highly significant improvement in time without worsening of disease, according to data released at the annual meeting of the American Association for Cancer Research. "Panitumumab is a new important treatment option for patients with chemo-resistant colorectal...

2005-11-03 14:13:13

CHICAGO (Reuters) - Amgen Inc. and Abgenix Inc. said on Thursday a late-stage study found its experimental drug panitumumab helped slow tumor progression in patients with advanced colon cancer who had failed multiple other therapies. In the 463-patient trial, patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone, the companies said. The result was better than the pre-set goal of a...

2005-06-13 16:29:09

Scientists have uncovered new information about a specific mechanism involved in the biology of malignant human tumor cells. The findings, published in the June issue of Cancer Cell, significantly advance knowledge about epidermal growth factor receptor (EGFR). EGFR is a well-studied cell surface receptor that stimulates cell growth by transmitting growth factor signals acting outside the cell. EGFR is often present at abnormally elevated levels in human cancer cells. Increased EGFR activity...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.